Here’s the press launch……..A brand new media platform servicing Australia’s burgeoning authorized hashish trade launches right this moment.

Cannabiz is the brainchild of Mumbrella co-founder and former CEO Martin Lane and KlickX founder Kim McKay.

It will inform, educate and join Australia’s authorized hashish sector by way of its web site weekly e-newsletter, podcast, market intelligence, trade reviews, networking occasions and enterprise consulting providers.

As effectively as its media properties, Cannabiz will supply PR and advertising and marketing recommendation to an trade which nonetheless operates in a extremely regulated promoting setting.

The platform might be accessible to member subscribers in 4 tiers – Essential, Advantage, Premium and The Green List. Other income will come from branded content material, occasions, coaching and consultancy.

The consultancy division will assist Cannabiz shoppers future proof their companies by introducing them to new methods of connecting with clients.

McKay stated: “The industry is at a tipping point. It is not a time for those who are afraid to challenge ideas and traditional approaches to business. That’s where Cannabiz comes in.”

Membership might be accessible to anybody working in Australia’s authorized hashish sector together with growers, producers, distributors, medical researchers, healthcare professionals, campaigners and political advocates.

Cannabiz will launch with an in-depth, three-part evaluation of Australia’s authorized hashish trade that includes unique insights from firm CEOs, politicians, commerce our bodies and campaigners.

The Cannabiz launch comes as a wave of regulatory reforms sweep Australia, main Government-backed medicinal hashish tasks get the inexperienced gentle and new industrial gamers enter the market.

In the primary quarter of 2020, the variety of medicinal hashish merchandise accessible for medical doctors to prescribe in Australia topped 100, with gross sales of A$150m anticipated by the tip of the yr*. Globally, the market is predicted to be price $US50 billion by 2025**.

It is at the moment authorized for medical doctors to prescribe medicinal hashish in Australia, however entry stays difficult for sufferers, forcing the bulk to supply it illegally.

A latest senate enquiry advisable downgrading medicinal hashish to schedule 3, that means it will be accessible behind the counter at pharmacies for the primary time.

McKay stated: “Not only are we solving a problem by providing clarity and guidance for a young industry with huge potential, we are also in the position to create meaningful change. Access to medicinal cannabis can improve and change the lives of many Australians.”

Lane added: “While there are websites aimed at the cannabis investment and medical communities, there’s nothing covering all aspects of the industry in Australia – growing, manufacturing, clinical trials, distribution, prescription, marketing and advocacy. There’s a whole ecosystem which we want to support and help grow.”

Source link